Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rimegepant for acute treatment of migraine in Japanese adults
jRCT2031220236Completed
- Sponsor
- Pfizer
- Start
- Aug 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial of rimegepant in migraine (3 arms), sponsored by Pfizer. Primary endpoint: Pain freedom at 2 hours post-dose. Started Aug 2022; status: completed.
02
Drugs
rimegepant
03
Conditions
migraine
Beyond the preview
Go deeper on jRCT2031220236.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031220236.